Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A personalized brain stimulation treatment for PTSD just got FDA clearance — and its clinical trial results are turning heads. The therapy, called Magnetic e-Resonance Therapy (MeRT), delivered a 52% reduction in PTSD symptoms and a 68% remission rate. For the estimated 13 million Americans living with PTSD, this marks the first FDA-cleared non-medication treatment option.
A personalized brain stimulation system for PTSD has received FDA clearance, offering a drug-free alternative for the millions of Americans who haven't found relief through medications or psychotherapy. Developed by Wave Neuroscience in collaboration with Texas A&M Health, the technology — called Magnetic e-Resonance Therapy (MeRT) — uses EEG brain mapping combined with an AI-assisted algorithm to customize transcranial magnetic stimulation (TMS) protocols for each patient.
Unlike standard TMS, which follows a one-size-fits-all approach, MeRT tailors magnetic pulses to an individual's unique brain activity patterns. In the clinical trial, participants underwent five sessions per week for five to six weeks, with improvements reported to persist after treatment ended. Researchers describe it as the first FDA-cleared non-medication PTSD treatment — a meaningful distinction given that current FDA-approved options are limited to two SSRIs.
By the Numbers:
Why it matters: Existing PTSD treatments leave many patients behind — medications carry side effects, and psychotherapy has high dropout rates. MeRT's strong early results and personalized approach could represent a meaningful step forward in psychiatric care, with researchers eyeing future applications in depression and anxiety as well.
